Some US biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the drugs watchdog under the Trump administration may delay regulatory reviews, executives, investors, and consultants told Reuters.
The US Food and Drug Administration is seen as the global gold standard for drug regulation and companies typically seek American approval first because it provides access to
